This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alemzadeh, R.
Right arrow Articles by Wyatt, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alemzadeh, R.
Right arrow Articles by Wyatt, D. T.
Related Collections
Right arrow Endocrinology
PEDIATRICS Vol. 114 No. 1 July 2004, pp. e91-e95

ELECTRONIC ARTICLE

Beneficial Effects of Continuous Subcutaneous Insulin Infusion and Flexible Multiple Daily Insulin Regimen Using Insulin Glargine in Type 1 Diabetes

Ramin Alemzadeh, MD, James N. Ellis, MSW, Mary K. Holzum, BSN, CDE, Elaine A. Parton, RN, MA, CPNP and David T. Wyatt, MD

From the Children’s Hospital of Wisconsin Diabetes Center, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

Objective. The aim of this study was to evaluate the metabolic effects of continuous subcutaneous insulin infusion (CSII) with flexible multiple daily insulin (FMDI; premeal lispro + bedtime glargine) therapy as determined by glycosylated hemoglobin (HbA 1c), body mass index (BMI), and hypoglycemic episodes in a group of patients who made the transition from multiple daily insulin (premeal lispro + bid ultralente) to either CSII or FMDI therapy.

Methods. Data from 40 (27 female and 13 male) patients (10.1–17.8 years of age) who were on CSII and 40 age- and gender-matched (27 female and 13 male) patients (10.3–17.3 years of age) who were on FMDI were collected during regularly scheduled visits at a similar frequency over a 1-year period.

Results. The total daily insulin dose did not change in CSII (0.97 ± 0.24 vs 0.91 ± 0.22 U/kg) and FMDI (0.98 ± 0.21 vs 0.97 ± 0.21 U/kg) patients, whereas the bolus:basal insulin ratio was significantly increased in both CSII (1.01 ± 0.43 vs 1.32 ± 0.52) and FMDI (1.07 ± 0.0.41 vs 1.29 ± 0.47) patients. The total cohort of CSII patients showed a decrease in HbA1c from 8.4 ± 1.0% to 7.8 ± 0.8%, whereas the FMDI cohort did not show a significant change in HbA1c (8.5 ± 1.1% to 8.2 ± 0.9%). However, 40% of the CSII group and 22.5% of the FMDI group showed ≥1.0% improvement in HbA1c. Also, a similar number of patients in CSII (52.5%; 8.0 ± 1.1 to 7.2 ± 0.5%) and FMDI (47.5%; 8.0 ± 0.5% to 7.5 ± 0.4%) maintained or achieved target HbA1c values <8.0%. The BMI increased significantly in the CSII group (21.6 ± 3.2 vs 23.0 ± 3.0 kg/m2) but did not change in the FMDI group (21.9 ± 3.9 vs 22.6 ± 3.8 kg/m2). There was a significant reduction in the rate of severe hypoglycemia (events/100 patient-years) in both cohorts: 20.6 to 8.2 in the CSII and 18.8 to 7.5 in the FMDI. Similarly, the rate of moderate hypoglycemia decreased in both CSII (68.3–35.4) and FMDI (56.3–30.4).

Conclusions. CSII therapy resulted in a significant improvement in HbA 1c in the entire group, whereas FMDI therapy improved HbA1c in only a subgroup of patients. However, almost half of the patients in each of the treatment groups maintained or achieved target glycemic control. Both CSII and FMDI treatment groups demonstrated a decreased rate of hypoglycemia without an abnormal increase in BMI. Although the design of this study does not allow direct comparison of the metabolic effects of CSII and FMDI therapies, both regimens seem to be superior to basal ultralente and lispro multiple daily insulin regimen and offer desirable therapeutic alternatives in pediatric diabetes care.

Key Words: type 1 diabetes • continuous subcutaneous insulin infusion • flexible multiple dose of insulin • hemoglobin A1c • glargine

Abbreviations: FMDI, flexible multiple daily insulin • HbA1c, glycosylated hemoglobin • CSII, continuous subcutaneous insulin infusion • DCCT, Diabetes Control and Complications Trial • MDI, multiple daily insulin • BMI, body mass index • ICR, insulin to carbohydrate ratio • TDD, total daily dose • DKA, diabetic ketoacidosis

Received for publication Feb 6, 2004; Accepted Feb 6, 2004.




This article has been cited by other articles:


Home page
 Diabetes CareHome page
S. Shalitin and M. Phillip
Hypoglycemia in Type 1 Diabetes: A still unresolved problem in the era of insulin analogs and pump therapy
Diabetes Care, February 1, 2008; 31(Supplement_2): S121 - S124.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
F. R. Cogen, C. Henderson, J. A. Hansen, and R. Streisand
Pediatric Quality of Life in Transitioning to the Insulin Pump: Does Prior Regimen Make a Difference?
Clinical Pediatrics, December 1, 2007; 46(9): 777 - 779.
[Abstract] [PDF]